217 related articles for article (PubMed ID: 21496448)
1. Intraoperative imaging of positron emission tomographic radiotracers using Cerenkov luminescence emissions.
Holland JP; Normand G; Ruggiero A; Lewis JS; Grimm J
Mol Imaging; 2011 Jun; 10(3):177-86, 1-3. PubMed ID: 21496448
[TBL] [Abstract][Full Text] [Related]
2. Cerenkov luminescence imaging of medical isotopes.
Ruggiero A; Holland JP; Lewis JS; Grimm J
J Nucl Med; 2010 Jul; 51(7):1123-30. PubMed ID: 20554722
[TBL] [Abstract][Full Text] [Related]
3. Cerenkov Luminescence Imaging as a Modality to Evaluate Antibody-Based PET Radiotracers.
D'Souza JW; Hensley H; Doss M; Beigarten C; Torgov M; Olafsen T; Yu JQ; Robinson MK
J Nucl Med; 2017 Jan; 58(1):175-180. PubMed ID: 27539844
[TBL] [Abstract][Full Text] [Related]
4. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of 89Zr-rituximab tracer by Cerenkov luminescence imaging and correlation with PET in a humanized transgenic mouse model to image NHL.
Natarajan A; Habte F; Liu H; Sathirachinda A; Hu X; Cheng Z; Nagamine CM; Gambhir SS
Mol Imaging Biol; 2013 Aug; 15(4):468-75. PubMed ID: 23471750
[TBL] [Abstract][Full Text] [Related]
6. Measuring the pharmacodynamic effects of a novel Hsp90 inhibitor on HER2/neu expression in mice using Zr-DFO-trastuzumab.
Holland JP; Caldas-Lopes E; Divilov V; Longo VA; Taldone T; Zatorska D; Chiosis G; Lewis JS
PLoS One; 2010 Jan; 5(1):e8859. PubMed ID: 20111600
[TBL] [Abstract][Full Text] [Related]
7. (68)Ga-labeled 3PRGD2 for dual PET and Cerenkov luminescence imaging of orthotopic human glioblastoma.
Fan D; Zhang X; Zhong L; Liu X; Sun Y; Zhao H; Jia B; Liu Z; Zhu Z; Shi J; Wang F
Bioconjug Chem; 2015 Jun; 26(6):1054-60. PubMed ID: 25853280
[TBL] [Abstract][Full Text] [Related]
8. Tumor uptake and tumor/blood ratios for [
Al-Saden N; Cai Z; Reilly RM
Nucl Med Biol; 2018 Dec; 67():43-51. PubMed ID: 30390575
[TBL] [Abstract][Full Text] [Related]
9. Cerenkov Luminescence Imaging (CLI) for cancer therapy monitoring.
Xu Y; Liu H; Chang E; Jiang H; Cheng Z
J Vis Exp; 2012 Nov; (69):e4341. PubMed ID: 23183774
[TBL] [Abstract][Full Text] [Related]
10. Correlation between positron emission tomography and Cerenkov luminescence imaging in vivo and ex vivo using 64Cu-labeled antibodies in a neuroblastoma mouse model.
Maier FC; Schmitt J; Maurer A; Ehrlichmann W; Reischl G; Nikolaou K; Handgretinger R; Pichler BJ; Thaiss WM
Oncotarget; 2016 Oct; 7(41):67403-67411. PubMed ID: 27602580
[TBL] [Abstract][Full Text] [Related]
11. Development and characterization of clinical-grade 89Zr-trastuzumab for HER2/neu immunoPET imaging.
Dijkers EC; Kosterink JG; Rademaker AP; Perk LR; van Dongen GA; Bart J; de Jong JR; de Vries EG; Lub-de Hooge MN
J Nucl Med; 2009 Jun; 50(6):974-81. PubMed ID: 19443585
[TBL] [Abstract][Full Text] [Related]
12. Comparative immuno-Cerenkov luminescence and -PET imaging enables detection of PSMA
Maier FC; Wild AM; Kirchen N; Holm F; Fuchs K; Schwenck J; Maurer A; Wiehr S
Appl Radiat Isot; 2019 Jan; 143():149-155. PubMed ID: 30445280
[TBL] [Abstract][Full Text] [Related]
13. Proof-of-concept study of monitoring cancer drug therapy with cerenkov luminescence imaging.
Xu Y; Chang E; Liu H; Jiang H; Gambhir SS; Cheng Z
J Nucl Med; 2012 Feb; 53(2):312-317. PubMed ID: 22241909
[TBL] [Abstract][Full Text] [Related]
14. Site-specifically labeled
Kristensen LK; Christensen C; Jensen MM; Agnew BJ; Schjöth-Frydendahl C; Kjaer A; Nielsen CH
Theranostics; 2019; 9(15):4409-4420. PubMed ID: 31285769
[TBL] [Abstract][Full Text] [Related]
15. Radiopharmaceutical and Eu
Shi X; Cao C; Zhang Z; Tian J; Hu Z
J Nanobiotechnology; 2021 Jul; 19(1):212. PubMed ID: 34271928
[TBL] [Abstract][Full Text] [Related]
16. Intratherapeutic biokinetic measurements, dosimetry parameter estimates, and monitoring of treatment efficacy using cerenkov luminescence imaging in preclinical radionuclide therapy.
Timmermand OV; Tran TA; Strand SE; Axelsson J
J Nucl Med; 2015 Mar; 56(3):444-9. PubMed ID: 25655628
[TBL] [Abstract][Full Text] [Related]
17. In vivo examination of (188)Re(I)-tricarbonyl-labeled trastuzumab to target HER2-overexpressing breast cancer.
Chen KT; Lee TW; Lo JM
Nucl Med Biol; 2009 May; 36(4):355-61. PubMed ID: 19423002
[TBL] [Abstract][Full Text] [Related]
18. Luminescence imaging using radionuclides: a potential application in molecular imaging.
Park JC; Il An G; Park SI; Oh J; Kim HJ; Su Ha Y; Wang EK; Min Kim K; Kim JY; Lee J; Welch MJ; Yoo J
Nucl Med Biol; 2011 Apr; 38(3):321-9. PubMed ID: 21492780
[TBL] [Abstract][Full Text] [Related]
19. Multispectral Cerenkov luminescence tomography for small animal optical imaging.
Spinelli AE; Kuo C; Rice BW; Calandrino R; Marzola P; Sbarbati A; Boschi F
Opt Express; 2011 Jun; 19(13):12605-18. PubMed ID: 21716501
[TBL] [Abstract][Full Text] [Related]
20. Sortase-Mediated Site-Specific Conjugation and
Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]